Palliative chemotherapy: Oxymoron or misunderstanding?

BMC Palliative Care

Volumn 15, Issue 1, 2016, Pages

  Roeland, Ej ^a   LeBlanc, Tw ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PATIENT CARE; PUBLICATION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; TERMINAL CARE; NEOPLASMS; PALLIATIVE THERAPY;

HUMANS; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 85008467220     PISSN: None     EISSN: 1472684X     Source Type: Journal    
DOI: 10.1186/s12904-016-0109-4     Document Type: Article

References (12)

1. Burris H, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403-13.
2. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2012;44:4869.
3. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2006;24:3831-7.
4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-26.
5. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol. 2012;30:1715-24.
6. Creutzfeldt A, Suling A, Oechsle K, et al. Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: A pilot study. BMC Palliat Care. 2016;15:1.
7. Prigerson HG, Bao Y, Shah MA, et al.: Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015;1(6):778-84. doi:10.1001/jamaoncol.2015.2378. https://www.ncbi.nlm.nih.gov/pubmed/ ?term=26203912.
8. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: The Project ENABLE II randomized controlled trial. JAMA. 2009;302:741-9.
9. Bakitas MA, Tosteson TD, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33:1438-45.
10. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-42.
11. Zimmermann C, Swami N, Krzyzanowska M, et al. Early palliative care for patients with advanced cancer: A cluster-randomised controlled trial. Lancet. 2014;383:1721-30.
12. Ferrell B, Sun V, Hurria A, et al. Interdisciplinary Palliative Care for Patients with Lung Cancer. J Pain Symptom Manage. 2015 Dec;50(6):758-67. doi:10. 1016/j.jpainsymman.2015.07.005. Epub 2015 Aug 19. https://www.ncbi.nlm. nih.gov/pubmed/26296261.